| Title |
Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States
|
|---|---|
| Published in |
PharmacoEconomics, November 2018
|
| DOI | 10.1007/s40273-018-0745-z |
| Pubmed ID | |
| Authors |
Holly Guy, Lydia Walder, Mark Fisher |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 20% |
| United States | 1 | 20% |
| Spain | 1 | 20% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 40% |
| Scientists | 2 | 40% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 49 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 18% |
| Student > Ph. D. Student | 7 | 14% |
| Student > Master | 7 | 14% |
| Student > Postgraduate | 4 | 8% |
| Other | 3 | 6% |
| Other | 5 | 10% |
| Unknown | 14 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 31% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 12% |
| Economics, Econometrics and Finance | 5 | 10% |
| Nursing and Health Professions | 2 | 4% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Other | 5 | 10% |
| Unknown | 14 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 January 2021.
All research outputs
#6,282,863
of 24,733,536 outputs
Outputs from PharmacoEconomics
#736
of 1,965 outputs
Outputs of similar age
#119,525
of 448,178 outputs
Outputs of similar age from PharmacoEconomics
#10
of 35 outputs
Altmetric has tracked 24,733,536 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 1,965 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 448,178 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.